Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report) and Progyny (PGNY – Research Report).
Insulet (PODD)
In a report issued on May 10, Matt Miksic from Barclays maintained a Hold rating on Insulet, with a price target of $200.00. The company’s shares closed last Friday at $165.90.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Currently, the analyst consensus on Insulet is a Strong Buy with an average price target of $236.92.
See the top stocks recommended by analysts >>
Progyny (PGNY)
In a report issued on May 10, Stephanie Davis from Barclays maintained a Buy rating on Progyny, with a price target of $30.00. The company’s shares closed last Friday at $27.53.
According to TipRanks.com, Davis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $41.71, representing a 74.5% upside. In a report issued on May 9, BTIG also maintained a Buy rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PODD:
